Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. Also provided are methods for vaccination of mammalian species, especially human patients, with variants of the E. coli FimH protein, said variants being derived from different strains of E. coli, and to production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A plasmid-based method of producing polypeptides, especially fused polypeptides, such as the complex of a bacterial chaperone and a bacterial adhesin, is also disclosed.

Abstract: The invention is directed to a composition and method for the treatment and prevention of inflammation and inflammatory related disorders. The composition is glucosamine in combination with an egg product. It is generally preferred that the egg product is obtained from an avian which has been hyperimmunized with an immungenic mixture and/or which contains an anti-inflammatory composition.

Abstract: Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.

Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis, including Crohn's disease.

Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.

Abstract: The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.

Abstract: The present invention provides a process for production of immunoglobulin A in milk from hyperimmunised mammals, using a three-route immunisation protocol. Also provided is milk containing immunoglobulin A produced by the process of the invention. These products are useful in producing formulations for passive immunisation against the selected pathogens. These formulations are further useful for preparation of further processed products.

Abstract: Effective antitoxins are demonstrated for prophylactic or causal immunotherapy. A method of generating antitoxin composed of highly-pure antibodies is described as an important defense against naturally-occurring plant and/or bacterial toxins.

Abstract: The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral cavity and/or pharynx.

Abstract: An egg-derived transfer factor, compositions including the egg-derived transfer factor, and methods for generating and preparing the egg-derived transfer factor. The egg-derived transfer factor may have specificity for one or more antigens. A method of using the egg-derived transfer factor includes administering either antigen-specific egg-derived transfer factor or antigen non-specific egg-derived transfer factor to animals, such as mammals, to treat or prevent pathogenic infections in the animals.

Abstract: The present invention provides specific antibodies obtained from eggs laid by hens which have been immunized against urease of Helicobacter pylori as an antigen, and specific antibodies obtained from eggs laid by hens which have been immunized against flagella of Helicobacter pylori as an antigen. These antibodies are useful for the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers caused by infection of Helicobacter pylori. At least one organism selected from lactic acid bacteria, Enterococcuses, yeasts, and Baillus can be used along with the antibodies.

Abstract: A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals.

Abstract: A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals.

Abstract: A polypeptide has first and second domains which enable the polypeptide to be translocated into a target cell or which increase the solubility of the polypeptide, or both, and further enable the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.

Abstract: The present invention provides specific antibodies obtained from eggs laid by hens which have been immunized against urease of Helicobacter pylori as an antigen, and specific antibodies obtained from eggs laid by hens which have been immunized against flagella of Helicobacter pylori as an antigen. These antibodies are useful for the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers caused by infection of Helicobacter pylori . At least one organism selected from lactic acid bacteria, Enterococcuses, yeasts, and Baillus can be used along with the antibodies.

Abstract: The present invention is drawn to avian vitellin antibodies that are immunologically reactive with HIV antigens, a process for the preparation thereof, a use thereof and a food substance in the form of a hen's egg containing the antibodies. The antibodies of the present invention are produced by immunizing hens with HIV antigens, in particular HIV core antigens and concentrating the antibodies in the egg yolk. The antibodies are suitable for passive immunization of mammals.

Abstract: The present invention provides a process for producing immunoglobulin A from hyperimmunized mammals using a 3 route immunization protocol. Also provided is immunoglobulin A and milk containing immunoglobulin A produced by the processes of the invention. These products are useful in producing formulations useful for passive immunization against selected pathogens.

Abstract: Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of colitis.

Abstract: A method for reducing gastrointestinal inflammation in an animal is disclosed. The method involves administering to the animal an agent that reduces the bioavailability in the animal of a prostaglandin or leukotriene lipid precursor wherein the agent comprises an antibody.

Abstract: Methods are described for preventing and treating necrotizing enterocolitis in animals, including humans. Antibodies directed to PAF and/or TNF are shown to have a beneficial effect in animal models predictive of human therapy for the treatment of necrotizing enterocolitis, which is a major life-threatening illness in neonates worldwide.

Abstract: Use of a CHV antigen for the preparation of a vaccine against canine herpesvirosis, which is intended to be administered to gestating bitches as close as possible to whelping, preferably during the final third of gestation, and which produces a high level of anti-CHV antibodies in gestating bitches at the time of whelping, inducing protection in the puppies by transfer of antibodies during suckling. Inactivated anti-CHV vaccine or subunit vaccines, which can be used for vaccinating gestating bitches to protect the puppies by transfer of antibodies.

Abstract: The present invention relates to dairy compositions and, more particularly, to dairy compositions containing colostrum. The applicant has discovered that colostrum can be processed so as to reduce the bioburden of liquid colostrum while retaining the biological activity of certain proteins including the immunoglobulin fraction. By this process it is possible to introduce liquid colostrum into pasteurized and unpasteurized dairy products. In one aspect of the invention there is provided a process for the preparation of a liquid colostrum product, suitable for inclusion in dairy products, which process includes subjecting colostrum to centrifugation to substantially reduce the microbial content thereof.

Abstract: The present invention relates to dairy compositions and, more particularly, to dairy compositions containing colostrum. The applicant has discovered that colostrum can be processed so as to reduce the bioburden of liquid colostrum while retaining the biological activity of certain proteins including the immunoglobulin fraction. By this process it is possible to introduce liquid colostrum into pasteurized and unpasteurized dairy products. In one aspect of the invention there is provided a process for the preparation of a liquid colostrum product, suitable for inclusion in dairy products, which process includes subjecting colostrum to centrifugation to substantially reduce the microbial content thereof.